The DesCAARTes phase 1 clinical trial is investigating CAAR-T therapy in pemphigus, in which patient T-cells are being engineered to recognise anti-desmoglein 3, which is expressed by B-cells that produce anti-desmoglein 3 (https://clinicaltrials.gov/ct2/show/NCT04422912). Here, DSG3 is linked to pemphigus.